xilio is a waltham, massachusetts-based biopharmaceutical company focused on defeating cancer. the company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, xilio, derived from the latin term, ex nihilo, meaning creation or big-bang. xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. to learn more, please visit www.xiliotx.com.
Company profile
Ticker
XLO
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Xilio Securities Corporation • Xilio Development, Inc. ...
IRS number
851623397
XLO stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
15 Apr 24
S-8
Registration of securities for employees
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
1 Apr 24
8-K
Other Events
28 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
8-K
Departure of Directors or Certain Officers
3 Jan 24
8-K
Other Events
7 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
Latest ownership filings
SC 13G
GILEAD SCIENCES, INC.
5 Apr 24
SC 13G/A
Rock Springs Capital Management LP
5 Apr 24
4
Change in insider ownership
3 Apr 24
3
Initial statement of insider ownership
3 Apr 24
SC 13G
Rock Springs Capital Management LP
14 Feb 24
4
Change in insider ownership
9 Feb 24
SC 13G/A
Octagon Capital Advisors LP
6 Feb 24
SC 13G/A
Octagon Capital Advisors LP
5 Feb 24
4
Change in insider ownership
16 Jan 24
4
Christopher James Frankenfield
3 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 61.35 mm | 61.35 mm | 61.35 mm | 61.35 mm | 61.35 mm | 61.35 mm |
Cash burn (monthly) | 5.20 mm | 6.61 mm | 5.79 mm | 7.01 mm | 4.46 mm | 6.12 mm |
Cash used (since last report) | 34.75 mm | 44.17 mm | 38.66 mm | 46.85 mm | 29.77 mm | 40.87 mm |
Cash remaining | 26.61 mm | 17.18 mm | 22.70 mm | 14.50 mm | 31.58 mm | 20.48 mm |
Runway (months of cash) | 5.1 | 2.6 | 3.9 | 2.1 | 7.1 | 3.3 |
Institutional ownership, Q2 2023
73.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 37 |
Opened positions | 2 |
Closed positions | 2 |
Increased positions | 3 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 39.73 bn |
Total shares | 25.39 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bain Capital Life Sciences Investors | 2.81 mm | $7.35 bn |
Atlas Venture Life Science Advisors | 2.76 mm | $7.23 bn |
Octagon Capital Advisors | 2.43 mm | $6.35 bn |
Atlas Venture Fund XI | 2.02 mm | $33.29 mm |
FMR | 1.91 mm | $5.00 bn |
SV7 Impact Medicine Fund | 1.61 mm | $26.54 mm |
MRL Ventures Fund | 1.48 mm | $0.00 |
TAK Takeda Pharmaceutical | 1.48 mm | $23.60 mm |
RiverVest Venture Fund IV | 1.44 mm | $23.71 mm |
RiverVest Venture Management | 1.44 mm | $3.78 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Gilead Sciences | Common Stock | Buy | Acquire P | No | No | 0.76 | 485,250 | 368.79 k | 7,345,473 |
2 Apr 24 | Gilead Sciences | Prefunded Warrants Common Stock | Buy | Acquire P | No | No | 0.7599 | 3,882,450 | 2.95 mm | 3,882,450 |
8 Feb 24 | Atlas Venture Fund XI | Common Stock | Sell | Dispose S | Yes | No | 0.64 | 267 | 170.88 | 734,546 |
8 Feb 24 | Atlas Venture Fund XI | Common Stock | Sell | Dispose S | No | No | 0.64 | 733 | 469.12 | 2,019,563 |
12 Jan 24 | Atlas Venture Fund XI | Common Stock | Sell | Dispose S | Yes | No | 0.83 | 560 | 464.80 | 734,813 |
12 Jan 24 | Atlas Venture Fund XI | Common Stock | Sell | Dispose S | No | No | 0.83 | 1,540 | 1.28 k | 2,020,296 |
11 Jan 24 | Atlas Venture Fund XI | Common Stock | Sell | Dispose S | Yes | No | 0.87 | 569 | 495.03 | 735,373 |
11 Jan 24 | Atlas Venture Fund XI | Common Stock | Sell | Dispose S | No | No | 0.87 | 1,566 | 1.36 k | 2,021,836 |
1 Jan 24 | Katarina Luptakova | RSU Common Stock | Grant | Acquire A | No | No | 0 | 66,500 | 0.00 | 66,500 |
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
9 Apr 24
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
1 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
1 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
29 Mar 24
12 Health Care Stocks Moving In Friday's Intraday Session
29 Mar 24
Press releases
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
1 Apr 24
Thinking about buying stock in RPM International, Xilio Therapeutics, KULR Technology, Torrid Holdings, or IGM Biosciences?
1 Apr 24
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
28 Mar 24
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
28 Mar 24
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
28 Feb 24